- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02648243
Impact of a Pharmacist-delivered Discharge and Follow-up Intervention for Patients With Acute Coronary Syndromes in Qatar
Impact of a Pharmacist-delivered Discharge and Follow-up Intervention for Patients With Acute Coronary Syndromes in Qatar: a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Nothing is known about the impact of Qatar clinical pharmacists as direct patient-care team members at discharge and post-discharge on the short-term and long-term outcomes of patients with ACS at Heart Hospital in Qatar. This research project aims to determine this.
The investigators hypothesize that a clinical pharmacist-delivered intervention consisting of medication reconciliation and counseling at discharge and tailored follow-up post-discharge will decrease hospital readmissions, emergency department (ED) visits and all-cause mortality at 3 months, 6 months and 12 months after hospital discharge when compared with control arm and pharmacist delivered intervention at discharge only among ACS patients. The investigators also hypothesize that the effect of the intervention will increase patients' adherence to evidence-based secondary prevention medications for CAD, and patient satisfaction with pharmacy services. besides, this intervention will reduce the treatment burden on patients.
Study objectives:
- To evaluate the effectiveness of clinical pharmacist-delivered intervention at discharge and tailored follow-up post-discharge on decreasing hospital readmissions, ED visits and mortality in ACS patients.
- To evaluate the effectiveness of the intervention on improving patient adherence to evidence-based secondary prevention CAD medications.
- To study the effect of the intervention on reducing the burden of treatment on patients.
- To assess the effect of the intervention on increasing patient satisfaction with pharmacy services at Heart Hospital in Qatar.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Doha, Qatar, 2713
- Dr. Maguy El Hajj
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 years of age
- Admitted to and discharged from any nonsurgical cardiology service at Heart Hospital with a diagnosis of ACS in the period from September 2015 to February 2016.
Exclusion Criteria:
- Severe visual impairment
- Severe hearing impairment
- Inability to communicate in English or Arabic
- Mental or psychiatric illness
- Delirium or severe dementia
- Cognitive impairment
- Incomprehensible speech
- Planned discharge to a location other than home (e.g. long-term care facility, nursing home, other medicine units etc.)
- Plan for coronary artery bypass graft (CABG) surgery during hospitalization
- Plan to leave Qatar in the next 12 months
- A terminal illness with a high likelihood of death in the next 12 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Patients will receive routine discharge instructions and medication information by the nurses and treating physicians at hospital discharge: Patients will not have any contact with the clinical pharmacists.
|
|
No Intervention: Pharmacist delivered usual care at discharge
Patients will receive the usual counseling at discharge by the clinical pharmacists.
|
|
Experimental: structured intervention at discharge and tailored follow up
The pharmacist will deliver a structured personalized discharge intervention in addition to 2 follow-up session (around 30 minutes each session) at 4 weeks of discharge and 8 weeks of discharge.
|
At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc. The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause hospitalizations and cardiac-related hospital readmissions
Time Frame: 3 months post discharge
|
This will be measured by the number (%) of hospital readmissions including hospitalizations for cardiac events, including coronary events, exacerbation of heart failure or arrhythmia.
Coronary events will be defined as ACS, percutaneous coronary intervention, and/or coronary artery bypass graft.
This outcome will be assessed by checking the Heart Hospital (HH) and Hamad Medical Corporation (HMC) medical records
|
3 months post discharge
|
All-cause hospitalizations and cardiac-related hospital readmissions
Time Frame: 6 months post discharge
|
This will be measured by the number (%) of hospital readmissions including hospitalizations for cardiac events, including coronary events, exacerbation of heart failure or arrhythmia.
Coronary events will be defined as ACS, percutaneous coronary intervention, and/or coronary artery bypass graft.
This outcome will be assessed by checking the Heart Hospital (HH) and Hamad Medical Corporation (HMC) medical records
|
6 months post discharge
|
All-cause hospitalizations and cardiac-related hospital readmissions
Time Frame: 12 months post discharge
|
This will be measured by the number (%) of hospital readmissions including hospitalizations for cardiac events, including coronary events, exacerbation of heart failure or arrhythmia.
Coronary events will be defined as ACS, percutaneous coronary intervention, and/or coronary artery bypass graft.
This outcome will be assessed by checking the Heart Hospital (HH) and Hamad Medical Corporation (HMC) medical records
|
12 months post discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality including cardiac-related mortality
Time Frame: 3 months, 6 months, and 12 months post discharge
|
This outcome will be measured by the number (%) of deaths.
It will be assessed by checking HH and HMC medical records during the designated follow-up periods.
•
|
3 months, 6 months, and 12 months post discharge
|
ED visits including cardiac-related ED visits
Time Frame: 3 months, 6 months, and 12 months post discharge
|
This outcome will be measured by the number (%) of ED visits.
The outcome will be assessed by checking HH and HMC medical records
|
3 months, 6 months, and 12 months post discharge
|
Patient adherence to evidence-based secondary prevention medications for CAD
Time Frame: 3 months, 6 months, and 12 months post discharge
|
Adherence will be measured from the refill records as well as by asking the patients to list the medications they are currently taking and by using the ARMS tool
|
3 months, 6 months, and 12 months post discharge
|
Burden of medications
Time Frame: 3 months, 6 months, and 12 months post discharge
|
will be assessed using a questionnaire that will be adapted from a validated and translated questionnaire.
|
3 months, 6 months, and 12 months post discharge
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Qatar U
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndromes
-
Virginia Commonwealth UniversityBracco Diagnostics, IncTerminatedCoronary Artery Disease | Acute Coronary SyndromesUnited States
-
Lene HolmvangCompletedCoronary Artery Disease | Percutaneous Coronary Intervention | Acute Coronary SyndromesDenmark
-
Shanghai Zhongshan HospitalActive, not recruiting
-
AstraZenecaCompletedAcute Coronary SyndromesKorea, Republic of
-
Yaling HanUnknownAcute Coronary SyndromesChina
-
Centre Hospitalier Universitaire de BesanconCompletedAcute Coronary SyndromesFrance
-
Samsung Medical CenterUnknownAcute Coronary SyndromesKorea, Republic of
-
Sahlgrenska University Hospital, SwedenAstraZenecaCompletedAcute Coronary SyndromesSweden
-
Xijing HospitalUnknown
-
Dr. Sanjit S. JollyMcMaster University; Population Health Research InstituteCompleted
Clinical Trials on Structured intervention at discharge and tailored follow up post discharge
-
Dokuz Eylul UniversityHacettepe University; Cukurova University; Gazi University; Ataturk University; Ege... and other collaboratorsUnknownCOPD Exacerbation | Chronic Respiratory Failure | Noninvasive Ventilation | Long Term Oxygen TherapyTurkey
-
Mount Sinai Hospital, CanadaCrohn's and Colitis CanadaUnknownInflammatory Bowel Diseases | Crohn Disease | Colitis, UlcerativeCanada
-
University College CorkUniversity Hospital, Ghent; University Hospital WaterfordRecruitingMultimorbidity | PolypharmacyBelgium, Ireland
-
University of ChicagoWashington University School of Medicine; Agency for Healthcare Research and... and other collaboratorsNot yet recruitingCOPD Exacerbation | Care TransitionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruitingAcute Myocardial InfarctionChina
-
Brigham and Women's HospitalOhio State UniversityActive, not recruitingOpioid Dependence | Opioid Use | Opioid-use DisorderUnited States
-
Methodist Health SystemEnrolling by invitationRenal Tumor | Loin Pain-Hematuria Syndrome | Renal Vascular Disease | Nutcracker Syndrome, Renal | Pelvic Trauma | Congestion, VenousUnited States
-
Medtronic Spinal and BiologicsMedtronic Bakken Research CenterRecruitingSpinal Deformity | Spinal Degenerative Disorder | Spinal Trauma | Spinal Fusion Failure | Spinal Tumor CaseUnited States
-
Providence Health & ServicesTerminated
-
Columbia UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...Completed